The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Official Title: Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer
Study ID: NCT01395030
Brief Summary: This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.
Detailed Description: PRIMARY OBJECTIVES: I. Determine the most optimal fluorine-18 (18F) fluoromethylcholine (FCH) PET/CT parameters for detecting primary hepatocellular carcinoma (HCC) by conducting a clinical radiologic-pathologic correlation study to estimate and compare the receiver operating characteristics of kinetic and static PET measures of tumor FCH metabolism in patients that test positive during screening or conventional imaging. II. Identify cancer signaling pathways associated with choline metabolism in HCC by profiling the global gene expression patterns in fresh-frozen liver tissue samples that are correlated with the features derived from FCH PET/CT images. III. Characterize the association between features derived from FCH PET/CT images of the liver and clinical liver disease severity and comparatively evaluate the ability of corresponding gene expression signatures to predictively model HCC disease outcome. OUTLINE: Patients undergo 18F-fluoromethylcholine PET/CT within 14 days of surgical resection. After completion of study treatment, patients are followed up periodically.
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Hawaii Cancer Center, Honolulu, Hawaii, United States
Name: Sandi Kwee, MD
Affiliation: Queen's Medical Center
Role: PRINCIPAL_INVESTIGATOR